©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2021; 27(40): 6844-6860
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6844
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6844
Role of human nucleoside transporters in pancreatic cancer and chemoresistance
Carly Jade Carter, Ahmed H Mekkawy, David L Morris, Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, University of New South Wales, Sydney 2217, New South Wales, Australia
Carly Jade Carter, Ahmed H Mekkawy, David L Morris, Mucpharm Pty Ltd, Australia
Author contributions: Carter CJ wrote the manuscript and designed the figures with the support of Mekkawy AH; Mekkawy AH and Morris DL revised and supervised the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: Morris DL is one of the inventors of BromAc and owns stocks in Mucpharm. Carter CJ and Mekkawy AH are employees of Mucpharm Pty Ltd.
Corresponding author: David L Morris, FRCS, FRCS (Ed), MBChB, MD, PhD, Professor, Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, University of New South Wales, Kogarah, Sydney 2217, New South Wales, Australia.
Received: February 17, 2021
Peer-review started: February 17, 2021
First decision: April 5, 2021
Revised: April 19, 2021
Accepted: September 14, 2021
Article in press: September 14, 2021
Published online: October 28, 2021
Processing time: 252 Days and 4.3 Hours
Peer-review started: February 17, 2021
First decision: April 5, 2021
Revised: April 19, 2021
Accepted: September 14, 2021
Article in press: September 14, 2021
Published online: October 28, 2021
Processing time: 252 Days and 4.3 Hours
Core Tip
Core Tip: Pancreatic cancer continues to be one of the leading causes of cancer-related mortality worldwide, with prevalence expected to increase drastically within the next decade primarily due to difficulties in diagnosis and acquired resistance to chemotherapeutic drugs. Due to this, in-depth work is extremely important for the future diagnosis and treatment of the disease. Human Nucleoside Transporters have been identified as a key target in not only diagnosis but also overcoming chemoresistance. Here, we summarize the information currently available on Pancreatic Cancer and the role of Nucleoside Transporters in chemoresistance.